Speaker: Persephone du Parcq, Lead Clinical/Translational Scientist, Synnovis, UK
In this webinar, Dr. Persephone du Parcq shares how Synnovis has deployed the "MSK-ACCESS™ powered with SOPHiA DDM™ to support precision oncology through minimally invasive liquid biopsy testing.
The webinar explores current clinical applications of ctDNA analysis, its demonstrated utility in routine healthcare, and key considerations around assay selection, validation strategies, and interpretation challenges including germline findings and clonal haematopoiesis. Practical insights into clinical impact, operational achievements to date, and lessons learned from clinical implementation are also discussed.
Finally, the session looks ahead to future directions for liquid biopsy in oncology, including opportunities to expand clinical adoption and improve patient care through advanced genomic technologies.

SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures unless specified otherwise.
SOPHiA DDM™ Dx Hereditary Cancer Solution, SOPHiA DDM™ Dx RNAtarget Oncology Solution and SOPHiA DDM™ Dx Homologous Recombination Deficiency Solution are available as CE-IVD products for In Vitro Diagnostic Use in the European Economic Area (EEA), the United Kingdom and Switzerland. SOPHiA DDM™ Dx Myeloid Solution and SOPHiA DDM™ Dx Solid Tumor Solution are available as CE-IVD products for In Vitro Diagnostic Use in the EEA, the United Kingdom, Switzerland, and Israel. Information about products that may or may not be available in different countries and if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact us to obtain the appropriate product information for your country of residence.
All third-party trademarks listed by SOPHiA GENETICS remain the property of their respective owners. Unless specifically identified as such, SOPHiA GENETICS’ use of third-party trademarks does not indicate any relationship, sponsorship, or endorsement between SOPHiA GENETICS and the owners of these trademarks. Any references by SOPHiA GENETICS to third-party trademarks is to identify the corresponding third-party goods and/or services and shall be considered nominative fair use under the trademark law.